In this randomized, placebo-controlled replicate trial, depemokimab decreased the annual rate of exacerbations among patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback